Many Patients Unable to Manage Disease

JUNE 01, 2005

Despite many advances in treating diabetes, the majority of adults with the disease have not reached the appropriate HbA1C goal. Reporting in the American Journal of Managed Care (April 2005), Kaiser Permanente conducted the first head-to-head analysis of the use of all current available treatments for diabetes. The study involved 4775 members of Kaiser Permanente Northern California Group.

The study's findings showed that >80% of badly controlled adults with type 2 diabetes who started new antidiabetic therapies did not achieve recommended glycemic targets (HbA1C ≤7%) within 1 year. The researchers suggested the need for more aggressive and earlier intensification of established therapies; less waiting time with quick progression from single therapy to combination therapy with or without insulin; and further investigation of ways to incorporate behavioral change.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.